bearish
Aurobindo Pharma (ARBP IN): Regulatory Issues Continue to Haunt the Company
298 Views15 May 2022 18:17
SUMMARY
- Aurobindo Pharma (ARBP IN) has been issued six observations for its oral manufacturing unit by the FDA, which will further impact its business. The company closed its New Jersey facility.
- Aurobindo’s recent acquisition of Veritaz Health for INR1.7 billion does not really fit for the company's high hope for the domestic formulation business.
- Aurobindo shares are trading at a forward P/E of 10.9x, which is cheaper than the peers. However, the company is not expected to see multiple expansion in near future.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Aurobindo Pharma (ARBP IN): Q3 Net Profit Dropped; R&D Cost To Remain Elevated in Near-Term02 Mar 2023
- Aurobindo Pharma (ARBP IN): Regulatory Issues Continue to Haunt the Company15 May 2022
- Aurobindo-Veritaz Acquisition: No Justice30 Mar 2022
- Aurobindo Pharma (ARBP IN): Pain Continues in the U.S. Formulation Business03 Mar 2022
x